The human neuroblastoma cell line CHP100 provides a useful model system in which to study the molecular mechanisms of transcriptional regulation of the low-affinity nerve growth factor receptor (NGFR) gene during neuronal development. Basic fibroblast growth factor (bFGF) induced morphological changes in CHP100 cells, including flattening of cell bodies and neurite outgrowth. bFGF also increased p75NGFR immunoreactivity, as assessed by immunocytochemistry, and increased p75NGFR mRNA levels, as assessed by Northern (RNA) blot analysis. A chimeric gene consisting of 6.7 kb of the 5'-flanking region of the human NGFR gene linked to the chloramphenicol acetyltransferase gene was constructed. In stable transformants of CHP100 cells, 10 ng of bFGF per ml induced an eightfold increase in chloramphenicol acetyltransferase activity. These results indicate that upstream elements of the NGFR gene mediate transcriptional regulation by bFGF.
Growth factors and their cognate receptors show highly programmed patterns of expression and play crucial regulatory roles in tissue growth and differentiation during vertebrate embryogenesis. Recent evidence suggests that development of the peripheral nervous system is under the control of a variety of growth factors. Basic fibroblast growth factor (bFGF) and acidic FGF have been shown to initiate the differentiation of neonatal chromaffin cells into immature sympathetic neurons, which in turn require nerve growth factor (NGF) for survival and maturation (15, 57) .
In a v-myc-immortalized sympathoadrenal precursor cell line, bFGF was found to elevate levels of mRNA encoding the 75-kDa low-affinity NGF receptor (p75NGFR) (5) . On the basis of these studies, Anderson and coworkers have proposed that bFGF (or a similar factor) and NGF act sequentially during differentiation of sympathetic neurons. Recent studies in our laboratory have demonstrated that the timing of expression of receptors for bFGF and NGF in developing chicken embryo sympathetic ganglia is consistent with the proposed sequential action of these factors. Embryonic sympathetic ganglia cells initially express relatively high levels of FGF receptor mRNA but only low levels of p75NGFR mRNA. Subsequently, levels of p75NGFR mRNA increase while expression of FGF receptor mRNA ceases (30) .
NGF is a member of a family of structurally related neurotrophic factors (neurotrophins), including brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), and neurotrophin-5 (NT-5) (for recent reviews, see references 3, 27, and 31). Cellular responses to NGF are apparently mediated by high-affinity receptors generated by the interaction of p75 GF with the 140-kDa protein encoded by the trk proto-oncogene (p140'rk) (29) . p75NGFR binds all neurotrophins with similar affinity (3, t Present address: Department of Pathology, University of Washington, Seattle, WA 98195. 31 ). Additional members of the trk gene family, trkB and trkC, encode receptors for BDNF, NT-3, NT-4, and NT-5 (3, 31, 36, 37, 55, 56) . A functional role for p75NGFR in facilitating cellular actions of BDNF, NT-3, NT-4, and NT-5 mediated by trkB and trkC receptors has been suggested (7) but not yet demonstrated.
Although many experiments have been carried out using rat pheochromocytoma (PC12) cells as a model for sympathetic neuronal differentiation, these cells have substantial levels of p75NGFR expression in the absence of bFGF and attain equivalent degrees of neuronal differentiation in response to NGF and bFGF (47) . Thus, they are not an suitable model of sympathetic neuronal stem cells with respect to some responses to bFGF and NGF. For this reason, we sought to identify an alternative in vitro system utilizing neuroblastoma cells which is more suitable for study of some elements of the mechanism of sympathetic neuronal differentiation. Owing to their neural crest origin, various human neuroblastoma cell lines have been used as models for peripheral neuron differentiation (44) . Several of these cell lines have been shown to be capable of undergoing neuronal differentiation following induction by factors such as NGF, retinoic acid, phorbol ester, cyclic AMP analogs, and protein kinase inhibitors (28, 45, 53, 54) . One of these cell lines, CHP100 (50), has been assigned to the subgroup of primitive neuroectodermal tumors which has cholinergic rather than adrenergic properties (46) . In this respect, these cells may resemble parasympathetic neurons or the cholinergic subpopulation of sympathetic neurons. However, our own unpublished results demonstrate that these cells also express the adrenergic marker, tyrosine hydroxylase. The coexpression of cholinergic and adrenergic traits is consistent with the behavior of immature sympathetic neurons (43) . Northern (RNA) blot and Western blot (immunoblot) analyses have shown that CHP100 cells express the endogenous NGF receptor (NGFR) gene (2) . However, as demonstrated in the present report, CHP100 cells express only relatively low levels of p75 NGFR, and expression of p75NG is substantially enhanced by bFGF. Thus, the CHP100 cell line provides a useful system for study of bFGF-initiated neuronal differentiation and stimulation of NGFR gene expression.
In the present study, using CHP100 cells as a model system for sympathetic neuron (48) . Briefly, cells were treated with 0.5% Nonidet P-40 and centrifuged to obtain nucleus-free supernatants, from which cytoplasmic RNA was purified by phenol-chloroform extraction. The RNA was fractionated on 1% agarose gels containing 6% formaldehyde and then electroblotted onto GeneScreen membranes (NEN). The membrane was soaked in methylene blue solution to stain rRNA in order to verify that equivalent amounts of RNA were transferred to the membrane in each lane. Construction of NGFR promoter-chlorampenicol acetyltransferase (CAT) DNA. X17A2 phage contains a portion of the genomic NGFR DNA sequence encompassing approximately 5.5 kb 5' to the mRNA cap site through the second exon of the coding region (Fig. 1A) (12, 52) . This clone, which contains the NGFR sequences as an EcoRI insert, was used as the starting material for the NGFR promoter constructs. The 4.3-kb BamHI fragment containing the NGFR promoter region (Fig. 1A ) was isolated from X17A2 and inserted into the unique BamHI site of pUC19. This plasmid was designated pBlOl. The AvaII site at nucleotide -43, located between the mRNA cap site (-121 and -122) and the initiator methionine codon (+1) (45) , was then converted to a Sall site via limited digestion of pBlOl with AvaIl, treatment with mung bean nuclease, and subsequent ligation of SalI 10-mer linkers (CGGTCGACCG: Stratagene catalog no. 901074) (Fig. 1B) . Following ligation of the SalI linkers, pBlOl was digested with Sall, and the 6.5-kb fragment was isolated and recircularized ( Fig. 1C ). This new plasmid, designated pRP2, contains the 3.8-kb NGFR promoter as a BamHI-SalI fragment, while lacking the first exon and the 5' portion of the first intron of the NGFR gene. It should be noted that pRP2 contains a HindIII site (from the pUC19 polylinker) immediately downstream of the Sall site on the 3' boundary of the NGFR promoter (Fig. 1C ). This plasmid also contains an NdeI site in the pUC19 sequences 5' to the NGFR promoter insert (Fig. 1C) .
pRSV-CAT (25) was modified to provide the vector for the NGFR promoter. In this plasmid, the Rous sarcoma virus (RSV) promoter is bounded on the 3' side by a HindIII site, while upstream of the RSV promoter is an NdeI site contained within the pBR322 sequences incorporated into the vector (25) (Fig. 1D ). In addition, a BamHI site is located in the vector sequences downstream of the CAT gene (Fig.  1D ). The RSV promoter region was excised from pRSV-CAT as an NdeI-HindIII fragment and replaced with the pRP2 NdeI-HindIII fragment containing the NGFR promoter (Fig. 1E ). This plasmid was designated phRCAT 5.4-kb BamHI fragment containing the NGFR promoter-CAT gene-simian virus 40 (SV40) splice site-SV40 polyadenylation site was then excised from phRCAT and inserted into the unique BamHI site of pUC19 (Fig. 1F ). This plasmid was designated pRCAT1.
The 4.6-kb EcoRI fragment was isolated from the 5' portion of the X17A2 genomic clone (Fig. 1A) and inserted into the unique EcoRI site of the pUC18 plasmid. Of the possible two orientations of the inserted EcoRI fragment, the clone in which the pUC19 polylinker is 5' to the 4.6-kb EcoRI fragment was designated pElOl (Fig. 1G) . The most 5'-fragment of the NGFR promoter was excised from pElOl as the 2.9-kb BamHI fragment (Fig. 1G) and inserted in the same orientation into the BamHI site at the 5' end of the insert DNA of pRCAT1 after limited digestion of the latter with BamHI. This final construct, designated pRBLCAT, contains the NGFR promoter within 6.7 kb of NGFR gene 5'-flanking sequence, and CAT gene-SV40 splice site-SV40 polyadenylation site (Fig. 1H) . The NGFR promoter contains neither TATA nor CAAT promoter elements (52) , and none were provided in this construction.
Transfection. CHP100 cells were transfected by the calcium phosphate-DNA precipitation method (62) . A total of 0.5 x 106 to 2 x 106 cells were plated into 100-mm-diameter RESULTS Morphological changes of CHP100 cells induced by bFGF. Diversity in cell morphologies is a hallmark of cultured neuroblastoma cells. Consistent with this, the cells of the neuroectodermal tumor line CHP100 display two distinct morphologies. As defined by others (4, 14) , the majority of cells (approximately 75%) adopt a neuroblastic cell (N-type) phenotype, being small and teardrop-shaped with short processes and loosely adherent cell bodies ( Fig. 2A) . The remaining cells display an intermediate (I-type) morphology, having small and slightly flattened cell bodies ( Fig. 2A) . These two cell types are interconvertible during culture, and this interchange is sensitive to the culture conditions. bFGF was found to induce profound morphological changes in CHP100 cells. After 24 h of incubation in medium containing 10 ng of bFGF per ml, some rapidly dividing round cells appeared. These cells were loosely attached to the monolayer of cells, eventually detached from the monolayer, and died within 48 h in the continued presence of bFGF. The remaining cells survived and ceased to divide but remained attached to the substrate. After 48 h of incubation with bFGF, these postmitotic cells possessed large flattened cell bodies, with some exhibiting enhanced elaboration of thick processes (Fig. 2C) . More marked morphological changes were observed after 96 h of incubation with bFGF ( Fig. 2D) . At this time, all cells were found to be more adherent to the substrate, with some of the cells continuing to extend thick processes. The proportion of these latter cells was greater when cells were plated at lower cell density. It was noted that regular replacement of the medium with medium containing additional bFGF was necessary to maintain these morphological changes; otherwise, weakly responding cells started dividing again and covered most of the substrate. NGF did not induce any morphological changes in CHP100 cells (Fig. 2B) (Fig. 3B) . While weak, this staining was significant when compared with negative control cells (Fig. 3A) immunostained with monoclonal antibody mc192 (11) . The latter antibody is directed against rat p75NGFR and cross-reacts poorly with human p75NGFR. Thus, we conclude that untreated CHP100 cells express their endogenous p75NGFR at low, but detectable, levels. In contrast, CHP100 cells treated with 10 ng of bFGF per ml for 48 h were stained significantly more strongly with NGFR5 antibody than were untreated control cells (Fig. 3C  and D) A more quantitative determination of the extent of induction of NGFR protein was accomplished using an enzymelinked immunoassay. CHP100 cells plated on gelatin in 96-well plates were exposed to various concentrations of bFGF for 2 days, and then the quantity of p75NGFR was determined immunochemically, as described in Materials and Methods. This assay revealed a threefold increase in the quantity of receptor protein per dish (Fig. 4) begin to distinguish among these possibilities, the effect of bFGF treatment on the steady-state level of p75NGFR mRNA was examined by Northern blot analysis. Cytoplasmic RNA was extracted from CHP100 cells following 48 or 96 h of incubation with or without bFGF, and p75NGFR mRNA was detected through hybridization with a 32P-labelled 0.9-kb p75NGFR cDNA fragment. A single faint 3.8-kb transcript was detected in untreated CHP100 (Fig. 5) . The size of this transcript is consistent with previous reports, which also detected a single 3.8-kb transcript in several different human neuroblastoma cells (2) and in a variety of primate tissues (49) . This 3.8-kb p75NGFR message was found to be increased in CHP100 cells following bFGF treatment (Fig. 5) promoter (52) (Fig. 1 ). This expression vector was designated pRBLCAT. Preliminary experiments showed that a low level of CAT activity was obtained in CHP100 cells transiently transformed with pRBLCAT (data not shown). This DNA, together with ptkneo, a plasmid conferring resistance to the antibiotic neomycin, was then introduced by transfection into CHP100 cells. Stably transformed clonal lines were selected by culture in G418, and several clonal lines were characterized. One cell line, NB6704, which showed the highest basal CAT activity among the stable transformants, was used to study the NGFR promoter activity in detail. The limited basal expression was subsequently used to normalize the CAT activities of bFGFtreated transformed cells. Figure 6 shows the relative CAT activities of extracts from NB6704 cells treated with different concentrations of bFGF for 24 h. bFGF is seen to increase CAT activity in a dose-dependent manner. Half-maximal CAT enhancement occurred at a dose of 3 ng of bFGF per ml, while 10 ng of bFGF per ml induced a maximum (approximately eightfold) of CAT activity. Experiments with several other cell lines stably transformed with pRBLCAT gave similar results, as did a pool of approximately 50 stably transformed colonies (data not shown).
A time course of CAT induction is shown in Fig. 7 . NB6704 cells incubated with 10 ng of bFGF per ml showed increased CAT activity approximately 6 h posttreatment, with maximal activity being achieved following 24 h of treatment. A half-maximal increase in CAT activities was obtained after 12 h of incubation with bFGF.
To rule out the possibility that bFGF might somehow directly stimulate activity of the CAT enzyme, the level of CAT mRNA was examined through Northern blot analysis of NB6404 cell cytoplasmic RNA using a CAT DNA probe. days yielded elevated levels of CAT mRNA to approximately the same extent as previously observed for NGFR mRNA (Fig. 8) . The largest and most abundant transcript corresponds to the expected 1.6-kb CAT mRNA; two smaller transcripts, of unknown origin, were consistently observed, in constant proportion to the amount of 1.6-kb mRNA. These may possibly arise by RNA splicing or from downstream sites of transcription initiation. By densitometric analysis of the 1.6-kb message, increases of approximately two-and threefold were found to be induced by treatment with 5 and 10 ng of bFGF per ml for 48 h, respectively, while three-and fivefold increases were observed after treatment with 5 and 10 ng of bFGF per ml for 96 h, respectively.
The effect of bFGF on CAT activity was compared with that of NGF. Figure 9 shows the relative CAT activities of NB6704 cells treated for 24 (33) , high levels of expression of bFGF have been found in early stages of mammalian and avian development (24, 32) , and expression of FGF receptors is widely distributed in Effects of bFGF and NGF on relative CAT activities in NB6704 transformants. NB6704 transformants were not treated (CONT). or were treated with bFGF (10 ng/ml), NGF (100 ng/ml), or both bFGF (10 ng/ml) and NGF (100 ng/ml) for 24 h. Relative CAT activities were expressed as described in the legend to Fig. 5. early stages of development (30, 42) . A family of factors with substantial structural similarity to bFGF and acidic FGF has been described, including Int-2 (19), the hst gene product (8, 58) , , , and keratinocyte growth factor (23) . Several members of the FGF family, including acidic FGF and the hst gene product may act on cells employing the same receptor used by bFGF (20) .
Among the potential roles of bFGF in embryonic development, bFGF or bFGF-related factors have been proposed to function in primary mesodermal induction (17, 33) . Injection of antibodies to bFGF interferes with normal embryonic development, providing direct evidence for the involvement of bFGF in developmental regulation (38) .
bFGF may play an important role as a mitogen and peurotrophic factor for the progenitor cells of both the central and peripheral nervous system (1, 30, 41, 51, 60, 61 (57) . A v-myc-immortalized cell line of rat sympathoadrenal progenitor was used in further analyses of sympathetic neuronal differentiation, in which bFGF was found to induce growth of neuritic processes and increase the level of p75NGFR mRNA (5) . These observations suggest that FGF is initially required for triggering the differentiation process and inducing p75 NG R expression. The development of neural crest-derived migrating precursor cells of sympathetic ganglia involves a determinative interaction with the ventral neural tube and somitic mesenchyme (6, 43) . It seems reasonable to suggest that this interaction may be mediated in part by bFGF or a similar factor.
Although NGF is also known to be an important factor for the development and maintenance of sympathetic neurons, NGF is not essential in early developmental stages but is required in later stages (6, 16, 43) . In vitro studies have demonstrated that cultured chick sympathetic neurons taken from an early stage of development showed little response to NGF (22) , and the appearance of adrenergic cells in culture was found to be independent of NGF (13) . Indeed, sympathetic neurons may not be exposed to NGF until after target innervation is complete (35) . All these observations are consistent with the view that NGF is involved only in the final stages of neuronal maturation, subsequent to bFGFinduced enhancement of NGFR expression. The finding that FGF receptors and NGFRs are sequentially expressed in the developing avian central nervous system as they are in the sympathetic nervous system (30) suggests that sympathetic neurons may also serve as a useful model for interactions between FGF and neurotrophin systems in the central nervous system.
In the present study, untreated CHP100 cells were found to express low levels of both p75NGFR protein ( Fig. 3B and 4 ) and p75NGFR mRNA (Fig. 5 ), in agreement with previous observations (2) . We have shown that bFGF induces marked morphological changes in CHP100 cells (Fig. 2) 
